The DOI matches its Crossref record; 314 of the 314 references it cites were found in a registry or an index.
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Open accessAbstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,254
(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124 · cited 2×
“III (3876) Reduced risk of stroke and myocardial infarction among non-diabetic patients with high CVD risk [96]”
BackgroundLindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetologia · doi:10.1007/s00125-014-3460-0 · Cited by 694
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome
Mihai, S., Codrici, E., Popescu, I. D., Enciu, A.-M., Albulescu, L., Necula, L. G., Mambet, C., Anton, G., & Tanase, C. (2018) · Journal of Immunology Research · doi:10.1155/2018/2180373 · Cited by 673
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Watson, G. S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 597
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Nissen, S. E. (2005) · JAMA · doi:10.1001/jama.294.20.joc50147 · Cited by 556
Mirza, A. Z., Althagafi, I. I., & Shamshad, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.067 · Cited by 544
Sayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
Celaya, F. B. (1989) · Anales de Medicina Interna · Cited by 508
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Demetri, G. D., Fletcher, C. D. M., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., & Singer, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3951 · Cited by 495
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Wilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke · doi:10.1161/01.str.0000257974.06317.49 · Cited by 475
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X.-P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180329197 · Cited by 426
Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M., Craig, J. C., Maggo, J., Gray, V., De Berardis, G., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 420
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis
Corpechot, C., Carrat, F., Bahr, A., Chrétien, Y., Poupon, R.-E., & Poupon, R. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.009 · Cited by 390
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Risérus, U., Sprecher, D., Johnson, T., Olson, E., Hirschberg, S., Liu, A., Fang, Z., Hegde, P., Richards, D., Sarov-Blat, L., et al. (2008) · Diabetes · doi:10.2337/db07-1318 · Cited by 325
Chew, E. Y., Davis, M. D., Danis, R. P., Lovato, J. F., Perdue, L. H., Greven, C., Genuth, S., Goff, D. C., Leiter, L. A., Ismail-Beigi, F., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.019 · Cited by 324
A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
Basaranoglu, M., Acbay, O., & Sonsuz, A. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80243-8 · Cited by 305
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramirez, G., & DeFronzo, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
Primary biliary cirrhosis: an orchestrated immune response against epithelial cells
Gershwin, M. E., Ansari, A. A., Mackay, I. R., Nakanuma, Y., Nishio, A., Rowley, M. J., & Coppel, R. L. (2000) · Immunological Reviews · doi:10.1034/j.1600-0528.2002.017402.x · Cited by 277
Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S., Nicolaides, A. N., Mahmood, S., Richmond, W., Mather, H., Sharp, P., Feher, M. D., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.641 · Cited by 271
Hirschfield, G. M., & Heathcote, E. J. (2010) · Evidence‐Based Gastroenterology and Hepatology · doi:10.1002/9781444314403.ch32 · Cited by 261
A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
Fernández-Miranda, C., Pérez-Carreras, M., Colina, F., López-Alonso, G., Vargas, C., & Solís-Herruzo, J. A. (2008) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.10.002 · Cited by 256
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Sugii, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S.-H., Castro, G. L., Yin, Y.-Q., Nelson, M. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912487106 · Cited by 255
Lee, M., Saver, J. L., Towfighi, A., Chow, J., & Ovbiagele, B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.020 · Cited by 240
PPAR-α as a Key Nutritional and Environmental Sensor for Metabolic Adaptation
Contreras, A. V., Torres, N., & Tovar, A. R. (2013) · Advances in Nutrition · doi:10.3945/an.113.003798 · Cited by 236
Lincoff, A. M., Tardif, J.-C., Schwartz, G. G., Nicholls, S. J., Rydén, L., Neal, B., Malmberg, K., Wedel, H., Buse, J. B., Henry, R. R., et al. (2014) · JAMA · doi:10.1001/jama.2014.3321 · Cited by 231
Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., Lashner, B., Present, D. H., Chuai, S., Ellenberg, J. H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.012 · Cited by 229
Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024038127156 · Cited by 228
Schütz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2038-05.2005 · Cited by 225
Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Target Genes of Peroxisome Proliferator-activated Receptor γ in Colorectal Cancer Cells
Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M., & DuBois, R. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103779200 · Cited by 215
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients
Raji, A., Seely, E. W., Bekins, S. A., Williams, G. H., & Simonson, D. C. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.172 · Cited by 215
Ortega-González, C., Luna, S., Hernández, L., Crespo, G., Aguayo, P., Arteaga-Troncoso, G., & Parra, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1965 · Cited by 212
Motomura, W., Okumura, T., Takahashi, N., OBARA, T., & Kohgo, Y. (2000) · PubMed · doi:10.11501/3186319 · Cited by 209
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Meade, T., Zuhrie, R., Cook, C., & Cooper, J. (2002) · BMJ · doi:10.1136/bmj.325.7373.1139 · Cited by 208
Henry, R. R., Lincoff, A. M., Mudaliar, S., Rabbia, M., Chognot, C., & Herz, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60870-9 · Cited by 205
BENAYOUN, L., LETUVE, S., DRUILHE, A., BOCZKOWSKI, J., DOMBRET, M.-C., MECHIGHEL, P., MEGRET, J., LESECHE, G., AUBIER, M., & PRETOLANI, M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.8.2101070 · Cited by 204
Sprecher, D. L., Massien, C., Pearce, G., Billin, A. N., Perlstein, I., Willson, T. M., Hassall, D. G., Ancellin, N., Patterson, S. D., Lobe, D. C., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252790.70572.0c · Cited by 201
PPARδ Promotes Running Endurance by Preserving Glucose
Fan, W., Waizenegger, W., Lin, C. S., Sorrentino, V., He, M.-X., Wall, C. E., Li, H., Liddle, C., Yu, R. T., Atkins, A. R., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.006 · Cited by 198
Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., M. Saunders, A., Irizarry, M., Jeter, B., Zvartau-Hind, M., H. van Dyck, C., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 197
Bruckert, E., Labreuche, J., Deplanque, D., Touboul, P.-J., & Amarenco, P. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318202709f · Cited by 192
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 180
Cariou, B., Zaïr, Y., Staels, B., & Bruckert, E. (2011) · Diabetes Care · doi:10.2337/dc11-0093 · Cited by 172
Polikandriotis, J. A., Mazzella, L. J., Rupnow, H. L., & Hart, C. M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000177805.65864.d4 · Cited by 169
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-125 · Cited by 166
Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Dupuis, L., Dengler, R., Heneka, M. T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037885 · Cited by 160
A phase II trial with rosiglitazone in liposarcoma patients
Debrock, G., Vanhentenrijk, V, Sciot, R., Debiec-Rychter, M., Oyen, R., & Van Oosterom, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601306 · Cited by 160
Bays, H. E., Schwartz, S. L., Littlejohn, T. W., Kerzner, B., Krauss, R. M., Karpf, D. B., Choi, Y., Wang, X., Naim, S., & Roberts, B. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1061 · Cited by 155
Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M.-J., & Akhondzadeh, S. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.58 · Cited by 153
Chilcott, J. B., Tappenden, P., Jones, M. L., & Wight, J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80078-8 · Cited by 151
Robison, N. J., Campigotto, F., Chi, S. N., Manley, P. E., Turner, C. D., Zimmerman, M. A., Chordas, C. A., Werger, A. M., Allen, J. C., Goldman, S., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24794 · Cited by 151
Mizoguchi, M., Tahara, N., Tahara, A., Nitta, Y., Kodama, N., Oba, T., Mawatari, K., Yasukawa, H., Kaida, H., Ishibashi, M., et al. (2011) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.08.007 · Cited by 150
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
Iwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M., Ishibashi, H., Sakaida, I., Kuriyama, S., Ichida, T., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00305.x · Cited by 145
Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014665 · Cited by 143
Fruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Wettstein, G., Luccarini, J., Poekes, L., Faye, P., Kupkowski, F., Adarbes, V., Defrêne, E., Estivalet, C., Gawronski, X., Jantzen, I., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1057 · Cited by 140
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139
Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13465 · Cited by 139
de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 138
Kaul, U., Parmar, D., Manjunath, K., Shah, M., Parmar, K., Patil, K. P., & Jaiswal, A. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0884-3 · Cited by 137
Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136
Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease
Schneider, C. A., Ferrannini, E., DeFronzo, R. A., Schernthaner, G., Yates, J., & Erdmann, E. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060678 · Cited by 134
Bae, M., & Song, B. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.401 · Cited by 133
Wilcox, R., Kupfer, S., & Erdmann, E. (2008) · American Heart Journal · doi:10.1016/j.ahj.2007.11.029 · Cited by 130
Huang, J., Shiau, C., Yang, Y.-T. C., Kulp, S. K., Chen, K., Brueggemeier, R. W., Shapiro, C. L., & Chen, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007732 · Cited by 129
Smith, M. R., Manola, J. B., Kaufman, D. S., George, D. J., Oh, W. K., Mueller, E., Slovin, S. F., Spiegelman, B. M., Small, E. J., & Kantoff, P. W. (2004) · Cancer · doi:10.1002/cncr.20493 · Cited by 126
Effect of pioglitazone treatment on behavioral symptoms in autistic children.
Boris, M., Kaiser, C. C., Goldblatt, A., Elice, M. W., Edelson, S. M., Adams, J. B., & Feinstein, D. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-3 · Cited by 123
Hepatitis C Virus, Insulin Resistance, and Steatosis
Kralj, D., Jukić, L. V., Stojsavljević, S., Duvnjak, M., Smolić, M., & Bilić-Čurčić, I. (2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00051 · Cited by 123
Jani, R. H., Pai, V., Jha, P. R., Jariwala, G., Mukhopadhyay, S., Bhansali, A. K., & Joshi, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 120
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
Calza, L., Manfredi, R., & Chiodo, F. (2003) · AIDS · doi:10.1097/00002030-200304110-00010 · Cited by 120
Idılman, R., Mızrak, D., CORAPCIOGLU, D., Bektaş, M., Doğanay, B., Saykı, M., Çoban, Ş., Erden, E., Soykan, İ., Emral, R., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03723.x · Cited by 119
Pai, V., Paneerselvam, A., Mukhopadhyay, S., Bhansali, A. K., Kamath, D., Shankar, V., Gambhire, D., Jani, R. H., Joshi, S., & Patel, P. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813518680 · Cited by 119
Honda, A., Tanaka, A., Kaneko, T., Komori, A., Abe, M., Inao, M., Namisaki, T., Hashimoto, N., Kawata, K., Takahashi, A., et al. (2019) · Hepatology · doi:10.1002/hep.30552 · Cited by 119
Adiponectin Is Required for PPARγ-Mediated Improvement of Endothelial Function in Diabetic Mice
Wong, W. T., Tian, X. Y., Xu, A., Yu, J. Q., Lau, C. W., Hoo, R. L. C., Wang, Y., Lee, V. W. Y., Lam, K. S. L., Vanhoutte, P. M., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.05.009 · Cited by 117
Bougarne, N., Paumelle, R., Caron, S., Hennuyer, N., Mansouri, R. M., Gervois, P. P., Staels, B., Haegeman, G., & Bosscher, K. D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806742106 · Cited by 117
Alam, F., Islam, M. A., Mohamed, M., Ahmad, I., Kamal, M. A., Donnelly, R., IDRIS, I. R., & Gan, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41854-2 · Cited by 117
Aberg, J. A., Zackin, R. A., Brobst, S. W., Evans, S. R., Alston, B., Henry, W. K., Glesby, M. J., Torriani, F. J., Yang, Y., Owens, S., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.757 · Cited by 115
Smallridge, R. C., Copland, J. A., Brose, M. S., Wadsworth, J. T., Houvras, Y. J., Menefee, M. E., Bible, K. C., Shah, M. H., Gramza, A. W., Klopper, J. P., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1106 · Cited by 114
Cree‐Green, M., Zwetsloot, J. J., Herndon, D. N., Qian, T., Morio, B., Fram, R. Y., Sanford, A. P., Aarsland, A. A., & Wolfe, R. R. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000250409.51289.ca · Cited by 112
Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy
Gou, Q., Gong, X., Jin, J., Shi, J., & Hou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19610 · Cited by 112
Auwerx, J. H., Schoonjans, K., Fruchart, J., & Staels, B. (1996) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.3.81 · Cited by 111
Pozzi, A., Ibáñez, M. R., Gatica, A., Yang, S., Wei, S. D., Mei, S., Falck, J. R., & Capdevila, J. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701429200 · Cited by 109
PPAR-γ Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar Depression
Kemp, D. E., Schinagle, M., Gao, K., Conroy, C. M., Ganocy, S. J., Ismail‐Beigi, F., & Calabrese, J. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0158-2 · Cited by 109
Wakino, S., Hayashi, K., Kanda, T., Tatematsu, S., Homma, K., Yoshioka, K., Takamatsu, I., & Saruta, T. (2004) · Circulation Research · doi:10.1161/01.res.0000142313.68389.92 · Cited by 109
Tzimopoulou, S., Cunningham, V. J., Nichols, T. E., Searle, G. E., Bird, N., Mistry, P. C., Dixon, I. J., Hallett, W. A., Whitcher, B. J., Brown, A. P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100939 · Cited by 106
Lee, Y., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E., Cho, Y. M., & Lee, B. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 106
Hic-5 regulates an epithelial program mediated by PPARγPreprint
Drori, S., Girnun, G. D., Tou, L., Szwaya, J. D., Mueller, E., Kia, X., Shivdasani, R. A., & Spiegelman, B. M. (2005) · Genes & Development · doi:10.1101/gad.1240705 · Cited by 103
Calza, L., Manfredi, R., Colangeli, V., Tampellini, L., Sebastiani, T., Pocaterra, D., & Chiodo, F. (2005) · AIDS · doi:10.1097/01.aids.0000174451.78497.8f · Cited by 102
Activation of PPARγ increases PTEN expression in pancreatic cancer cells
Farrow, B. J., & Evers, B. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02983-2 · Cited by 102
Ravnskjær, K., Frigerio, F., Boergesen, M., Nielsen, T., Maechler, P., & Mandrup, S. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001123 · Cited by 101
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
Rousselot, P. H., Prost, S., Guilhot, J., Roy, L., Étienne, G., Legros, L., Charbonnier, A., Coiteux, V., Cony‐Makhoul, P., Huguet, F., et al. (2016) · Cancer · doi:10.1002/cncr.30490 · Cited by 101
Reichle, A., Bross, K., VOGT, T. M., Bataille, F., Wild, P. J., Berand, A., Krause, S. W., & Andreesen, R. (2004) · Cancer · doi:10.1002/cncr.20574 · Cited by 99
Grigorian, A. Y., Mardini, H. E., Corpechot, C., Poupon, R., & Levy, C. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.02.011 · Cited by 99
Yee, L. D., Williams, N., Wen, P., Young, D. C., Lester, J., Johnson, M. V., Farrar, W. B., Walker, M. J., Povoski, S. P., Suster, S. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1947 · Cited by 98
Rosiglitazone Add-On in Treatment of Depressed Patients with Insulin Resistance: a Pilot Study
Rasgon, N., Kenna, H. A., Williams, K. E., Powers, B. N., Wroolie, T., & Schatzberg, A. F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.32 · Cited by 97
Nishio, K., Sakurai, M., Kusuyama, T., Shigemitsu, M., Fukui, T., Kawamura, K., Itoh, S., Konno, N., & Katagiri, T. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1170 · Cited by 97
Gerber, J. G., Kitch, D. W., Fichtenbaum, C. J., Zackin, R. A., Charles, S., Hogg, E., Acosta, E. P., Connick, E., Wohl, D. A., Kojic, E. M., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815bace2 · Cited by 94
Okayasu, T., Tomizawa, A., Suzuki, K., Manaka, K., & Hattori, Y. (2008) · Life Sciences · doi:10.1016/j.lfs.2008.02.002 · Cited by 93
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Georgoula, M., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75078 · Cited by 91
Werzowa, J., Hecking, M., Haidinger, M., Lechner, F., Döller, D., Pacini, G., Stemer, G., Pleiner, J., Frantal, S., & Säemann, M. D. (2013) · Transplantation · doi:10.1097/tp.0b013e318276a20e · Cited by 87
Kim, S. G., Kim, D. M., Woo, J., Jang, H. C., Chung, C. H., Ko, K. S., Park, J. H., Park, Y. S., Kim, S. J., & Choi, D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092843 · Cited by 87
Bezafibrate in skeletal muscle fatty acid oxidation disorders
Ørngreen, M. C., Madsen, K. L., Preisler, N. R., Andersen, G., Vissing, J., & Laforêt, P. (2014) · Neurology · doi:10.1212/wnl.0000000000000118 · Cited by 87
Slama, L., Lanoy, É., Valantin, M., Bastard, J., Chermak, A., Boutekatjirt, A., Faltaos, D. W., Billaud, E., Molina, J., Capeau, J., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300107 · Cited by 86
Adjuvant pioglitazone for unremitted depression: Clinical correlates of treatment response
Watson, K. T., Wroolie, T., Robakis, T. K., & Rasgon, N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.013 · Cited by 85
Mittal, R., Malhotra, S., Pandhi, P., Kaur, I., & Dogra, S. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.5 · Cited by 85
Jun, I., Izumi, N., Nishimura, Y., Inoue, K., Ueda, K., Nakanishi, H., Tsuchiya, K., Hamano, K., Asahina, Y., Kurosaki, M., et al. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 85
Cardiovascular disease in lupus: insights and updates
Knight, J. S., & Kaplan, M. J. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328363eba3 · Cited by 84
Kebebew, E., Lindsay, S., Clark, O. H., Woeber, K. A., Hawkins, R. A., & Greenspan, F. S. (2009) · Thyroid · doi:10.1089/thy.2008.0371 · Cited by 83
Myopathy with statin–fibrate combination therapy: clinical considerations
Jacobson, T. A. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.151 · Cited by 82
Cho, L., Kilpatrick, E. S., Keevil, B. G., Coady, A., & Atkin, S. L. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03309.x · Cited by 81
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Cross‐Talk between PPARs and the Partners of RXR: A Molecular Perspective
Chan, L. S. A., & Wells, R. A. (2009) · PPAR Research · doi:10.1155/2009/925309 · Cited by 79
PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43
Joardar, A., Menzl, J., Podolsky, T. C., Manzo, E., Estes, P. S., Ashford, S., & Zarnescu, D. C. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu587 · Cited by 79
Tan, C. K., Zhuang, Y., & Wahli, W. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1280467 · Cited by 79
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 78
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin
Overbeck, K., Genné, D., Golay, A., & Negro, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.03.033 · Cited by 77
Ooi, E. M. M., Watts, G. F., Sprecher, D. L., Chan, D. C., & Barrett, P. H. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1131 · Cited by 77
Marder, W., Khalatbari, S. H., Myles, J. D., HENCH, R. P., Lustig, S., Yalavarthi, S., Parameswaran, A., Brook, R. D., & Kaplan, M. J. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000441 · Cited by 77
Cheng, H. S., Lee, J. X. T., Wahli, W., & Tan, N. S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0971-9 · Cited by 77
Self-citationLiu, J., & Wang, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010693.pub4 · Cited by 76
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 76
Self-citationGhaleiha, A., Rasa, S. M., Nikoo, M., Farokhnia, M., Mohammadi, M.-R., & Akhondzadeh, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.07.043 · Cited by 75
Boggild, A. K., Krudsood, S., Patel, S. N., Serghides, L., Tangpukdee, N., Katz, K. C., Wilairatana, P., Liles, W. C., Looareesuwan, S., & Kain, K. C. (2009) · Clinical Infectious Diseases · doi:10.1086/605431 · Cited by 75
Pharmacological treatments for Friedreich ataxia
Kearney, M., Orrell, R. W., Fahey, M., Brassington, R., & Pandolfo, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007791.pub4 · Cited by 74
Jeschke, M. G., Kraft, R., Emdad, F., Kulp, G. A., Williams, F. N., & Herndon, D. N. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f2774c · Cited by 74
Olson, E. J., Pearce, G. L., Jones, N. P., & Sprecher, D. L. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.247890 · Cited by 74
Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
Liberopoulos, E. N., Florentin, M., Elisaf, M., Mikhailidis, D. P., & Tsianos, E. V. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010120 · Cited by 73
Schmitz, J. M., Green, C. E., Hasan, K. M., Vincent, J. N., Suchting, R., Weaver, M. F., Moeller, F. G., Narayana, P. A., Cunningham, K. A., Dineley, K. T., et al. (2017) · Addiction · doi:10.1111/add.13868 · Cited by 73
Pioglitazone Improves Left Ventricular Diastolic Function in Patients With Essential Hypertension
HORIO, T., Suzuki, M., SUZUKI, K., Takamisawa, I., Hiuge, A., Kamide, K., Takiuchi, S., Iwashima, Y., Kihara, S., & Funahashi, T. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.02.003 · Cited by 72
PPARγ, a Lipid‐Activated Transcription Factor as a Regulator of Dendritic Cell Function
Szatmári, I., Rajnavölgyi, É., & Nagy, L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1366.013 · Cited by 71
Badiou, S., Boever, C. M. D., Dupuy, A., Baillat, V., Cristol, J., & Reynes, J. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.10.006 · Cited by 71
Ji, L., Song, W., Fang, H., Li, W. S., Geng, J., Wang, Y., Guo, L., Cai, H., Yang, T., Li, H., et al. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.03.019 · Cited by 71
Goldstein, B. J., Rosenstock, J., Anzalone, D. A., Tou, C., & Öhman, K. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154169 · Cited by 70
Vascular insulin resistance in prehypertensive rats: Role of PI3-kinase/Akt/eNOS signaling
Li, R., Zhang, H., Wang, W., Wang, X., Huang, Y., Huang, C., & Gao, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.038 · Cited by 70
Foll, B. L., Ciano, P. D., Panlilio, L. V., Goldberg, S. R., & Ciccocioppo, R. (2013) · Current Drug Targets · doi:10.2174/1389450111314070006 · Cited by 70
A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
Kaiser, C. C., Shukla, D. K., Stebbins, G. T., Skias, D. D., Jeffery, D., Stefoski, D., Katsamakis, G., & Feinstein, D. L. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.04.011 · Cited by 68
Li, X.-J., Yu, Y.-X., Liu, C.-Q., Zhang, W., Zhang, H.-J., Yan, B., Wang, L.-Y., Yang, S.-Y., & Zhang, S.-H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03917.x · Cited by 67
A Meta‐Analysis of the Effect of Thiazolidinediones on Blood Pressure
Qayyum, R., & Adomaityte, J. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04784.x · Cited by 66
Pedersen, G., & Brynskov, J. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.749 · Cited by 66
Takagi, T., Okura, H., 小林, 芳., Kataoka, T., Taguchi, H., Toda, I., Tamita, K., Yamamuro, A., Sakanoue, Y., Ito, A., et al. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.04.007 · Cited by 65
Xiao, H., Wang, Q., Liu, Y., Zheng Rui, Y. O. U., Zhao Lian, B. I. A. N., Qiu, D., & Ma, X. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00574.x · Cited by 64
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
Clarke, G. D., Solis-Herrera, C., Molina-Wilkins, M., Martinez, S., Merovci, A., Cersosimo, E., Chilton, R. J., Iozzo, P., Gastaldelli, A., Abdul-Ghani, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0078 · Cited by 63
Balasubramanyam, A., Coraza, I., Smith, E. O., Scott, L. W., Patel, P., Iyer, D., Taylor, A. A., Giordano, T. P., Sekhar, R. V., Clark, P., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3067 · Cited by 63
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases
Maccallini, C., Mollica, A., & Amoroso, R. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0220-9 · Cited by 63
Sheth, S. H., & Larson, R. J. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-183 · Cited by 58
Gavrila, A., Hsu, W., Tsiodras, S., Doweiko, J. P., Gautam, S., Martin, L., Moses, A. C., Karchmer, A. W., & Mantzoros, C. S. (2005) · Clinical Infectious Diseases · doi:10.1086/427697 · Cited by 57
Dutta, K., Patel, P., & Julien, J.-P. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.008 · Cited by 56
Tanaka, R., Yamashiro, K., Okuma, Y., Shimura, H., Nakamura, S., Ueno, Y., Tanaka, Y., Miyamoto, N., Tomizawa, Y., Nakahara, T., et al. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.30007 · Cited by 56
Lonn, E., Gerstein, H. C., Sheridan, P., Smith, S. L., Díaz, R., Mohan, V., Bosch, J., Yusuf, S., & Dagenais, G. R. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.072 · Cited by 56
Cited by
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Targeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 504
Brase, R. A., Mullin, E. J., & Spink, D. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22030995 · Cited by 374
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
Metadata
- Authors
- Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-10-11
- Volume
- 20
- Issue
- 20
- Pages
- 5055
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2980024320
- Cited by
- 264
- References
- 314
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.